The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma

Uh Young Huh, Jin Hyuk Kim, Byung Ho Kim, Ki Deuk Nam, Jae Young Jang, Nam Hoon Kim, SangKil Lee, Kwang Ro Joo, Seok Ho Dong, Hyo Jong Kim, Young Woon Chang, Joung Il Lee, Rin Chang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Patients with hepatocellular carcinoma (HCC) may manifest paraneoplastic syndromes such as hypercholesterolemia, hypoglycemia, hypercalcemia and erythrocytosis. This study was aimed at evaluating the incidence and clinical significance of paraneoplastic syndromes in Korean HCC patients. METHODS: The medical records of 165 HCC patients who were diagnosed and died in the Kyung Hee University Hospital, were reviewed retrospectively. The following variables were analyzed: age, gender, hepatitis markers, platelet, liver function test, alpha-fetoprotein (AFP), Child-Pugh score, tumor features, and the duration of their survival. RESULTS: In total, paraneoplastic syndromes were presented in 43.6% of the HCC patients during the course of their disease. Hypercholesterolemia was solely presented in 14.5%, hypoglycemia in 12.7% and hypercalcemia in 7.8%. The patients who presented with more than 2 syndromes were 8.5%. While 80% of erythrocytosis (4/5) and 51.6% of hypercholesterolemia (16/31) was presented at the time of HCC diagnosis, hypoglycemia and hypercalcemia mainly occurred as terminal events. The patients with paraneoplastic syndromes were younger and had higher rates of portal vein thrombosis, bi-lobar tumor involvement and tumor more of more than 10 cm in diameter, compared to those patients without them. The proportion of patients with a serum AFP more than 400 ng/mL tended to be higher in the patients with paraneoplastic syndromes. The HCC patients with paraneoplastic syndromes, except for erythrocytosis, had a shorter survival than those patients without them. CONCLUSIONS: Paraneoplastic syndromes are not infrequently presented in HCC patients, especially at an advanced stage, and the survival of these patients is relatively shorter.

Original languageEnglish
Pages (from-to)275-283
Number of pages9
JournalThe Korean journal of hepatology
Volume11
Issue number3
Publication statusPublished - 2005 Jan 1

Fingerprint

Paraneoplastic Syndromes
Hepatocellular Carcinoma
Incidence
Polycythemia
Hypercalcemia
Hypercholesterolemia
Hypoglycemia
alpha-Fetoproteins
Survival
Platelet Function Tests
Neoplasms
Liver Function Tests
Portal Vein
Hepatitis
Medical Records

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Huh, U. Y., Kim, J. H., Kim, B. H., Nam, K. D., Jang, J. Y., Kim, N. H., ... Chang, R. (2005). The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma. The Korean journal of hepatology, 11(3), 275-283.
Huh, Uh Young ; Kim, Jin Hyuk ; Kim, Byung Ho ; Nam, Ki Deuk ; Jang, Jae Young ; Kim, Nam Hoon ; Lee, SangKil ; Joo, Kwang Ro ; Dong, Seok Ho ; Kim, Hyo Jong ; Chang, Young Woon ; Lee, Joung Il ; Chang, Rin. / The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma. In: The Korean journal of hepatology. 2005 ; Vol. 11, No. 3. pp. 275-283.
@article{fc95885f4f8e448da85cf3b9b88f947b,
title = "The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma",
abstract = "BACKGROUND/AIMS: Patients with hepatocellular carcinoma (HCC) may manifest paraneoplastic syndromes such as hypercholesterolemia, hypoglycemia, hypercalcemia and erythrocytosis. This study was aimed at evaluating the incidence and clinical significance of paraneoplastic syndromes in Korean HCC patients. METHODS: The medical records of 165 HCC patients who were diagnosed and died in the Kyung Hee University Hospital, were reviewed retrospectively. The following variables were analyzed: age, gender, hepatitis markers, platelet, liver function test, alpha-fetoprotein (AFP), Child-Pugh score, tumor features, and the duration of their survival. RESULTS: In total, paraneoplastic syndromes were presented in 43.6{\%} of the HCC patients during the course of their disease. Hypercholesterolemia was solely presented in 14.5{\%}, hypoglycemia in 12.7{\%} and hypercalcemia in 7.8{\%}. The patients who presented with more than 2 syndromes were 8.5{\%}. While 80{\%} of erythrocytosis (4/5) and 51.6{\%} of hypercholesterolemia (16/31) was presented at the time of HCC diagnosis, hypoglycemia and hypercalcemia mainly occurred as terminal events. The patients with paraneoplastic syndromes were younger and had higher rates of portal vein thrombosis, bi-lobar tumor involvement and tumor more of more than 10 cm in diameter, compared to those patients without them. The proportion of patients with a serum AFP more than 400 ng/mL tended to be higher in the patients with paraneoplastic syndromes. The HCC patients with paraneoplastic syndromes, except for erythrocytosis, had a shorter survival than those patients without them. CONCLUSIONS: Paraneoplastic syndromes are not infrequently presented in HCC patients, especially at an advanced stage, and the survival of these patients is relatively shorter.",
author = "Huh, {Uh Young} and Kim, {Jin Hyuk} and Kim, {Byung Ho} and Nam, {Ki Deuk} and Jang, {Jae Young} and Kim, {Nam Hoon} and SangKil Lee and Joo, {Kwang Ro} and Dong, {Seok Ho} and Kim, {Hyo Jong} and Chang, {Young Woon} and Lee, {Joung Il} and Rin Chang",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "11",
pages = "275--283",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "3",

}

Huh, UY, Kim, JH, Kim, BH, Nam, KD, Jang, JY, Kim, NH, Lee, S, Joo, KR, Dong, SH, Kim, HJ, Chang, YW, Lee, JI & Chang, R 2005, 'The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma', The Korean journal of hepatology, vol. 11, no. 3, pp. 275-283.

The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma. / Huh, Uh Young; Kim, Jin Hyuk; Kim, Byung Ho; Nam, Ki Deuk; Jang, Jae Young; Kim, Nam Hoon; Lee, SangKil; Joo, Kwang Ro; Dong, Seok Ho; Kim, Hyo Jong; Chang, Young Woon; Lee, Joung Il; Chang, Rin.

In: The Korean journal of hepatology, Vol. 11, No. 3, 01.01.2005, p. 275-283.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma

AU - Huh, Uh Young

AU - Kim, Jin Hyuk

AU - Kim, Byung Ho

AU - Nam, Ki Deuk

AU - Jang, Jae Young

AU - Kim, Nam Hoon

AU - Lee, SangKil

AU - Joo, Kwang Ro

AU - Dong, Seok Ho

AU - Kim, Hyo Jong

AU - Chang, Young Woon

AU - Lee, Joung Il

AU - Chang, Rin

PY - 2005/1/1

Y1 - 2005/1/1

N2 - BACKGROUND/AIMS: Patients with hepatocellular carcinoma (HCC) may manifest paraneoplastic syndromes such as hypercholesterolemia, hypoglycemia, hypercalcemia and erythrocytosis. This study was aimed at evaluating the incidence and clinical significance of paraneoplastic syndromes in Korean HCC patients. METHODS: The medical records of 165 HCC patients who were diagnosed and died in the Kyung Hee University Hospital, were reviewed retrospectively. The following variables were analyzed: age, gender, hepatitis markers, platelet, liver function test, alpha-fetoprotein (AFP), Child-Pugh score, tumor features, and the duration of their survival. RESULTS: In total, paraneoplastic syndromes were presented in 43.6% of the HCC patients during the course of their disease. Hypercholesterolemia was solely presented in 14.5%, hypoglycemia in 12.7% and hypercalcemia in 7.8%. The patients who presented with more than 2 syndromes were 8.5%. While 80% of erythrocytosis (4/5) and 51.6% of hypercholesterolemia (16/31) was presented at the time of HCC diagnosis, hypoglycemia and hypercalcemia mainly occurred as terminal events. The patients with paraneoplastic syndromes were younger and had higher rates of portal vein thrombosis, bi-lobar tumor involvement and tumor more of more than 10 cm in diameter, compared to those patients without them. The proportion of patients with a serum AFP more than 400 ng/mL tended to be higher in the patients with paraneoplastic syndromes. The HCC patients with paraneoplastic syndromes, except for erythrocytosis, had a shorter survival than those patients without them. CONCLUSIONS: Paraneoplastic syndromes are not infrequently presented in HCC patients, especially at an advanced stage, and the survival of these patients is relatively shorter.

AB - BACKGROUND/AIMS: Patients with hepatocellular carcinoma (HCC) may manifest paraneoplastic syndromes such as hypercholesterolemia, hypoglycemia, hypercalcemia and erythrocytosis. This study was aimed at evaluating the incidence and clinical significance of paraneoplastic syndromes in Korean HCC patients. METHODS: The medical records of 165 HCC patients who were diagnosed and died in the Kyung Hee University Hospital, were reviewed retrospectively. The following variables were analyzed: age, gender, hepatitis markers, platelet, liver function test, alpha-fetoprotein (AFP), Child-Pugh score, tumor features, and the duration of their survival. RESULTS: In total, paraneoplastic syndromes were presented in 43.6% of the HCC patients during the course of their disease. Hypercholesterolemia was solely presented in 14.5%, hypoglycemia in 12.7% and hypercalcemia in 7.8%. The patients who presented with more than 2 syndromes were 8.5%. While 80% of erythrocytosis (4/5) and 51.6% of hypercholesterolemia (16/31) was presented at the time of HCC diagnosis, hypoglycemia and hypercalcemia mainly occurred as terminal events. The patients with paraneoplastic syndromes were younger and had higher rates of portal vein thrombosis, bi-lobar tumor involvement and tumor more of more than 10 cm in diameter, compared to those patients without them. The proportion of patients with a serum AFP more than 400 ng/mL tended to be higher in the patients with paraneoplastic syndromes. The HCC patients with paraneoplastic syndromes, except for erythrocytosis, had a shorter survival than those patients without them. CONCLUSIONS: Paraneoplastic syndromes are not infrequently presented in HCC patients, especially at an advanced stage, and the survival of these patients is relatively shorter.

UR - http://www.scopus.com/inward/record.url?scp=33644918066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644918066&partnerID=8YFLogxK

M3 - Article

C2 - 16177554

AN - SCOPUS:33644918066

VL - 11

SP - 275

EP - 283

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 3

ER -